John Renger - Jul 5, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol: CERE
Transactions as of: Jul 5, 2022
Transactions value $: -$694,545
Form type: 4
Date filed: 7/7/2022, 04:06 PM
Previous filing: Apr 15, 2022
Next filing: Jul 22, 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$87.5K	+25K	+924.56%	$3.50^*	27.7K	Jul 5, 2022	Direct	F1, F2
transaction	CERE	Common Stock	Sale	-$750K	-25K	-90.24%	$30.00	2.7K	Jul 5, 2022	Direct	F1
transaction	CERE	Common Stock	Options Exercise	$3.87K	+1.11K	+40.87%	$3.50^*	3.81K	Jul 6, 2022	Direct	F1
transaction	CERE	Common Stock	Sale	-$35.9K	-1.11K	-29.01%	$32.50	2.7K	Jul 6, 2022	Direct	F1

Showing 1 to 4 of 4 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-25K	-13.1%	$0.00	166K	Jul 5, 2022	Common Stock	25K	$3.50	Direct	F1, F3
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-1.11K	-0.67%	$0.00	165K	Jul 6, 2022	Common Stock	1.11K	$3.50	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	Includes 724 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2022.
F3	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.